findmyKOL

Randall Urban, MD

Basic profile

The University of Texas Medical Branch at Galveston

ORCIDNPI
RegionGalveston, TX · South CentralSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2020Online presenceNot yet checkedPaymentsNone reportedNIH funding1992–2026Why? →

Randall Urban is an Endocrinology/Metabolic physician affiliated with The University of Texas Medical Branch at Galveston. OpenAlex indexes 224 publications with 11,752 citations (h-index 53); ClinicalTrials.gov lists 12 registered studies matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
224publications

Distinct works indexed by OpenAlex, matched via ORCID.

11,752citations

Total citations across indexed works.

53h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
12clinical trials

Investigator role on registered studies.

View trials
10NIH grants · 1992–2026

Federally funded research awards.

View funding

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Hormonal (systemic)

    55.3%
    Recombinant Human Growth Hormone35.1%
    Genotropin73%Omnitrope27%
    Part D<11 patients
    l-Thyroxine16.7%
    Levothyroxine Sodium73%Synthroid27%
    Part D<11 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    31.3%
    GLP-1 receptor agonist15.5%
    Ozempic64%Trulicity36%
    Part D<11 patients
    Biguanide (metformin)12.9%
    Metformin Hcl60%Metformin Hcl Er40%
    Part D<11 patients

    + 1 more class in this area

  • Cardiovascular

    13.4%
    Statin8.9%
    Atorvastatin Calcium100%
    Part D11 patients
    Angiotensin receptor blocker (ARB)4.5%
    Losartan Potassium100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

10 NIH research awards on record, funded 19922026 per NIH RePORTER. The latest:

107 more award records behind the reveal.Reveal →

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”